Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7073280 | 1.00 | SMN1; SMN2 (0.39) | — | |
| Hydrochloric Acid SCHEMBL1337777 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL159221 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL5276199 | 1.00 | SMN1; SMN2 (0.39) | — | |
| Hydrochloric Acid SCHEMBL159222 | 1.00 | — | — | |
| SCHEMBL186262 | 0.97 | — | — | |
| SCHEMBL159223 | 0.97 | — | — | |
| SCHEMBL47274 | 0.97 | — | — | |
| SCHEMBL2236696 | 0.95 | — | — | |
| Methylene Chloride SCHEMBL29028670 | 0.93 | KIF11 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332780-B | Synthesis method of S-3-chloro-D-alanine methyl ester hydrochloride | 河北国龙制药有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-118271200-A | Industrial preparation method and application of lacosamide | 北京澳合药物研究院有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-116332780-A | Synthesis method of S-3-chloro-D-alanine methyl ester hydrochloride | 河北国龙制药有限公司 | 2023-06-27 | — | — | CN | claimed |
| US-20130041180-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2013-02-14 | — | — | US | claimed |
| EP-2534127-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN Laboratories Limited (IN) | 2012-12-19 | — | — | EP | claimed |
| WO-2011099033-A1 | PROCESS FOR PREPARING (R)-2-ACETAMIDO-N-BENZYL-3-METHOXY-PROPIONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-08-18 | — | — | WO | claimed |
| CN-1329403-C | A method for preparing N-acyl lysophosphatidylcholine compound and a pharmaceutical composition containing the compound for treating metabolic bone disease | JHON GIL JA (KR) | 2007-08-01 | — | — | CN | claimed |
| CN-1608073-A | A method for preparing N-acyl lysophosphatidylcholine compound and a pharmaceutical composition containing the compound for treating metabolic bone disease | JHON GIL JA (KR) | 2005-04-20 | — | — | CN | claimed |
| US-20050014722-A1 | Process for preparing n-acylated lysophosphatidylcholine and pharmaceutical composition for treatment of metabolic bone disease comprising said compounds | JHON, GIL-JA (KR) | 2005-01-20 | — | — | US | claimed |
| WO-2003053984-A1 | A PROCESS FOR PREPARING N-ACYLATED LYSOPHOSPHATIDYLCHOLINE AND A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF METABOLIC BONE DISEASE COMPRISING SAID COMPOUNDS | JHON GIL-JA (KR) | 2003-07-03 | — | — | WO | claimed |
| US-20260146037-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | SHANGHAI YIDIAN PHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD (CN) | 2026-05-28 | — | — | US | disclosed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-04-09 | — | — | US | disclosed |
| US-12522594-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-01-13 | — | — | US | disclosed |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| US-4640913-A | Phosphocholine derivatives having antihypertensive action | AMERICAN CYANAMID COMPANY (US) | 1987-02-03 | — | — | US | disclosed |
| US-4551459-A | Method of treating heart failure using (2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-b]quinazolinyl)oxyalkylamides | SYNTEX (U.S.A.) INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0153152-A2 | (2-Oxo-1,2,3,5-tetrahydroimidazo-/2,1-b/quinnazolinyl)-oxyalkylamides, their preparation, compositions containing them and their use in making medicaments | SYNTEX (U.S.A.) INC. (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0144840-A2 | Optically active beta-lactams and method of their production | Takeda Chemical Industries, Ltd. (JP) | 1985-06-19 | — | — | EP | disclosed |
| EP-0116948-A2 | (2-Oxo-1,2,3,5-tetrahydroimidazo-(2,1-b)quinazolinyl)-oxyalkyl-amides | SYNTEX (U.S.A.) INC. (US) | 1984-08-29 | — | — | EP | disclosed |